Tag: the war on (some) drugs

A dream-like psychedelic might help traumatized veterans reset their brains

A new study suggests that the intensity of spiritual or “mystical” moments felt during psychedelic treatment may predict how well veterans recover from trauma symptoms. Researchers found that soldiers who reported profound feelings of unity and sacredness while taking ibogaine experienced lasting relief from post-traumatic stress disorder. These findings were published in the Journal of Affective Disorders.

For decades, medical professionals have sought better ways to assist military personnel returning from combat. Many veterans suffer from post-traumatic stress disorder, or PTSD, as well as traumatic brain injuries caused by repeated exposure to blasts. These conditions often occur together and can be resistant to standard pharmaceutical treatments. The lack of effective options has led some researchers to investigate alternative therapies derived from natural sources.

One such substance is ibogaine. This psychoactive compound comes from the root bark of the Tabernanthe iboga shrub, which is native to Central Africa. Cultures in that region have used the plant for centuries in healing and spiritual ceremonies. In recent years, it has gained attention in the West for its potential to treat addiction and psychiatric distress. Unlike some other psychedelics, ibogaine often induces a dream-like state where users review their memories.

Despite anecdotal reports of success, the scientific community still has a limited understanding of how ibogaine works in the human brain. Most prior research focused on classic psychedelics like psilocybin or MDMA. The specific psychological mechanisms that might allow ibogaine to alleviate trauma symptoms remain largely unexplored.

Randi E. Brown, a researcher at the Stanford University School of Medicine and the VA Palo Alto Health Care System, led a team to investigate this question. They worked in collaboration with the late Nolan R. Williams and other specialists in psychiatry and behavioral sciences. The team sought to determine if the subjective quality of the drug experience mattered for recovery. They hypothesized that a “mystical experience” might be a key driver of therapeutic change.

The concept of a mystical experience in psychology is specific and measurable. It refers to a sensation of unity with the universe, a transcendence of time and space, and deeply felt peace or joy. It also includes a quality known as ineffability, meaning the experience is too profound to be described in words. The researchers wanted to know if veterans who felt these sensations more strongly would see better clinical results.

The study analyzed data from thirty male Special Operations Veterans. All participants had a history of traumatic brain injury and combat exposure. Because ibogaine is not approved for medical use in the United States, the veterans traveled to a clinic in Mexico for the treatment. This setup allowed the researchers to observe the effects of the drug in a clinical setting outside the U.S.

The treatment protocol involved a single administration of the drug. The medical staff combined ibogaine with magnesium sulfate. This addition is intended to protect the heart, as ibogaine can sometimes disrupt cardiac rhythms. The veterans received the medication orally after a period of fasting. They spent the session lying down with eyeshades, generally experiencing the effects internally rather than interacting with others.

To measure the psychological impact of the session, the researchers administered the Mystical Experiences Questionnaire. This survey asks participants to rate the intensity of various feelings, such as awe or a sense of sacredness. The researchers collected these scores immediately after the treatment concluded.

Keep reading

Delaware Lawmakers Approve Bill To Decriminalize Public Marijuana Use And Remove Threat Of Jail Time

Delaware lawmakers have approved a bill to decriminalize public consumption of marijuana.

Under current law, Delaware is the only cannabis legalization state in the U.S. that imposes the threat of jail time for the public consumption, but the House Health & Human Development Committee voted 9-5 on Wednesday to advance legislation to change that.

While certain legal marijuana states like Colorado and Ohio still impose criminal penalties for public cannabis use, Delaware stands out as especially punitive, with a maximum penalty that carries the risk of jail time in addition to a fine.

Under HB 252, sponsored by Rep. Eric Morrison (D), the penalty would be reduced to a civil infraction, punishable by a $50 fine for a first offense and $100 fine for a second or subsequent offense.

Morrison told colleagues at Wednesday’s hearing that “it makes sense that if we’ve seen fit to decriminalize cannabis, that we decriminalize public consumption of it.”

“This legislation puts us in line with what the large majority of other states with decriminalized or legalized cannabis have done when it comes to public consumption,” he said.

“This change does not say it’s okay to consume cannabis in public. It simply updates the current penalty for public consumption to be commensurate with the offense,” Morrison said.

“There are bad things associated with a criminal record. Those things can include difficulty in finding work and difficulty in finding housing. There are also bad things, of course, associated with prison time. You’re taking away family members from their families. You’re taking them away from their jobs, possibly taking away income they need to meet the monthly bills, or maybe even causing them to lose their job.”

The Marijuana Policy Project (MPP) said in an action alert on Tuesday that the state’s current penalty is “out of step with Delaware’s treatment of secondhand tobacco smoke.”

Keep reading

Top Federal Drug Official Touts Therapeutic ‘Promise’ Of Psychedelics And Slams Schedule I Research Barriers

A top federal health official is again touting the therapeutic “promise” of psychedelics such as psilocybin and MDMA—though she says the drugs’ Schedule I status remains a research barrier to scientifically validating their efficacy.

In a blog post this month, National Institution on Drug Abuse (NIDA) Director Nora Volkow said the “potential use of psychedelics in the treatment of various mental health conditions has made these drugs a hot area of scientific research, as well as growing public interest.”

NIDA, as well as other agencies such as the Food and Drug Administration (FDA), have been particularly interested in tapping into the therapeutic potential of ketamine, psilocybin and MDMA—each of which are undergoing trials that could pave the path to their broader accessibility to patients with serious mental health conditions.

These psychedelics “represent a potential paradigm shift in the way we address substance use disorders,” Volkow said, caveating that “there is much we still do not know about these drugs, the way they work, and how to administer them, and there is danger of the hype getting out ahead of the science.”

The director said the “promise of psychedelic compounds likely centers on their ability to promote rapid neural rewiring,” which “may explain these compounds’ relatively long-lasting effects, even with just one or a few administrations.”

Keep reading

The Information War Over Antidepressants

Stat News hit the ethical and scientific bottom two weeks ago when they published an article by Stephen B. Soumerai, professor of population medicine at Harvard Medical School, and Christine Y. Lu, professor at the Sydney Pharmacy School of the University of Sydney.1

I have rarely seen so much disinformation in so few words, only 1,220. I reproduce the article in its entirety, in italics, with my comments. 

I do not consider Stat News a reliable news source. It has corporate ties, and despite its name, it has nothing to do with statistics, which I thought for ten years till I looked it up. Stat is short for Statim, which means immediate in Latin. 

The two professors have forgotten that professors have an obligation towards society to be honest conveyors of science. Their article is propaganda of the worst kind, which is apparent already in its title and subtitle: 

RFK Jr.’s war on antidepressants is coming – and it will cost lives. Kennedy’s rhetoric is not only based on bad science, it fuels distrust in mental health treatments.

It is primitive and a no-go for scientists to raise their voice by using war rhetoric but they continue with this in the first sentence of the article: 

While his war on vaccines may be getting more attention, health secretary Robert F. Kennedy Jr. is coming for another important medical tool: antidepressants. In November, he posted on X that the CDC is “finally confronting the long-taboo question of whether SSRIs and other psychoactive drugs contribute to mass violence.” We fear that in 2026, he may turn his rhetoric into action.

Kennedy has not started a war on vaccines.2-6 As health secretary, he has taken rational, much needed, and evidence-based initiatives. He fired the Advisory Committee on Immunization Practices (ACIP) at the Centers for Disease Control and Prevention (CDC) because it rubber-stamped all proposals that came to them and because some members had conflicts of interest in relation to vaccine manufacturers and other drug companies; dropped the much too broad recommendations for the Covid vaccine; cut funding for mRNA vaccines; stopped recommending the hepatitis B vaccine for all newborns; and reduced the huge childhood vaccine schedule that made the US an outlier compared to Europe. 

Moreover, it is well documented that SSRIs and other psychoactive drugs can cause violence.7-11 For antidepressants, the violence is dose-related,11 and it is highly relevant to study their role in mass shootings. Unfortunately, the authorities routinely refuse to release information about what drugs the mass murderers were on. It has become taboo to mention that psychiatric drugs kill people, indeed to such an extent that they are the third leading cause of death, after heart disease and cancer (much because elderly people may lose balance, break their hip, and die).12 

Keep reading

GOP Congressman Backs Effort To Roll Back Marijuana Legalization In Arizona—But Says Trump Holds ‘Power’ With Rescheduling Push

A GOP congressional lawmaker says he’d like to see his state of Arizona roll back its voter-approved marijuana legalization law with an initiative that could be on the November ballot—but he acknowledged that President Donald Trump’s recent federal rescheduling order could complicate that prohibitionist push.

Two Republican members of Arizona’s U.S. House delegation spoke with Marijuana Moment about the proposed ballot measure to eliminate commercial cannabis sales in the state, voicing opposition to legalization while recognizing that pending federal reform represents an obstacle for the anti-marijuana campaign.

Rep. Paul Gosar (R-AZ)—who was among a handful of GOP lawmakers who urged the Trump administration to reject rescheduling last year—said he would like to see voters approve an initiative to repeal the adult-use marijuana market in Arizona. That measure was filed with the secretary of state’s office last month, but it hasn’t been certified for ballot placement at this point.

“We need to really take a comprehensive look at cannabis all the way across the board. Science tries to commit one way or another to us, and we’re not getting the full background on it,” he said, adding that he still regards marijuana as a “gateway drug” to other illicit substances and arguing that the cannabis industry has “resisted every which way with the regulations.”

Asked about Trump’s recent executive order directing the attorney general to expeditiously finalize a rule moving cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA), the congressman conceded that could hamper the state-level repeal effort.

“He’s got power,” Gosar said. “But a lot of us want to know who was it that actually turned his ear” to support rescheduling.

The lawmaker said the president has historically been receptive to his input, and he’d like to have a discussion about the rescheduling move—but that’s yet to materialize.

Another congressional Republican representing Arizona, Rep. Andy Biggs (R-AZ), also weighed in on the rescheduling push in an interview with Marijuana Moment last week.

While there’s a libertarian perspective on the issue he appreciates when it comes to letting adults make their own choices about personal marijuana use, he said the fiscal conservative in him says prohibition can help prevent the use of taxpayer dollars to deal with what he characterized as the consequences of cannabis use.

“I’ve always taken the position that you need to keep marijuana where it was because the social safety network is in place, causing taxpayers to have to fund rehabilitation for those things,” he said.

Keep reading

US military kills two in latest strike on alleged drug-smuggling vessel, leaves one survivor

The United States Southern Command said Friday that two alleged “narco-terrorists” were killed in its latest kinetic strike on a vessel in the Eastern Pacific, and that one person survived.

The strike comes after the Trump administration faced scrutiny over the handling of an attack in September, where a second strike was conducted on a single drug ship to allegedly kill two survivors of the first strike. 

The strike was part of “Joint Task Force Southern Spear” which targets alleged drug-smuggling vessels in the Caribbean and Eastern Pacific. The military has conducted dozens of strikes in recent months, which have killed over 100 people.

“Intelligence confirmed the vessel was transiting along known narco-trafficking routes in the Eastern Pacific and was engaged in narco-trafficking operations,”  SOUTHCOM said on X. “Two narco-terrorists were killed and one survived the strike. Following the engagement, SOUTHCOM immediately notified [the U.S. Coast Guard] to activate the Search and Rescue system for the survivor.”

The Coast Guard has not commented on its rescue operation. 

Keep reading

Ex-DEA agent gets 5 years in prison for using badge to protect drug trafficking friends: “Little dark secret”

In two decades of kicking in doors for the U.S. Drug Enforcement Administration, Joseph Bongiovanni often took on the risks of being the “lead breacher,” meaning he was the first person into the room.

On Wednesday, he felt a familiar uncertainty awaiting sentencing for using his DEA badge to protect childhood friends who became prolific drug traffickers in Buffalo, New York.

“I never knew what was on the other side of that door — that fear is what I feel today,” Bongiovanni, 61, told a federal judge, pounding the defense table as his face reddened with emotion. “I’ve always been innocent. I loved that job.”

U.S. District Court Judge Lawrence J. Vilardo sentenced the disgraced lawman to five years in federal prison on a string of corruption counts. The punishment was significantly less than the 15 years prosecutors sought even after a jury acquitted Bongiovanni of the most serious charges he faced, including an allegation he pocketed $250,000 in bribes from the Mafia.

The judge said the sentence reflected the complexity of the mixed verdicts following two lengthy trials and the almost Jekyll-and-Hyde nature of Bongiovanni’s career, in which the lawman racked up enough front-page accolades to fill a trophy case.

Bongiovanni once hurtled into a burning apartment building to evacuate residents through billowing smoke. He locked up drug dealers, including the first ever prosecuted in the region for causing a fatal overdose.

“There are two completely polar opposite versions of the facts and polar opposite versions of the defendant,” Vilardo said, assuring prosecutors five years behind bars would pose a considerable hardship to someone who has never been to prison.

Keep reading

South Dakota Senate Panel Advances Bills To Ban Intoxicating Hemp And Kratom—But Without Recommendations For Passage

A South Dakota Senate panel advanced—but did not endorse—bans on hemp-derived intoxicants and kratom on Wednesday at the Capitol in Pierre.

Both bills were sponsored by Sen. John Carley, R-Piedmont.

The Senate Health and Human Services Committee voted unanimously to put the two prohibition bills in front of the full state Senate with no recommendation. Committees generally give a “do pass” recommendation to the bills they send out for a floor vote.

The votes came one day after the Senate Judiciary Committee offered its unqualified support for a bill meant to restrict the sale of certain hemp-based products to people older than 21. That bill came from Attorney General Marty Jackley (R).

In testimony about Carley’s bills, business owners and consumers of products like hemp-derived THC seltzers and kratom said they helped people kick opioids or alcohol. They also mentioned sales taxes collected on consumable products and the value of hemp to South Dakota farmers. That led some committee members to oppose the bills and sparked failed attempts to block the proposals. Ultimately, however, the committee opted to let the state Senate weigh in.

“We need to have a conversation about this on the floor,” said Sen. Curt Voight, R-Rapid City. “I think it rises to the level of a legislative decision.”

Possession, sale or use of kratom or THC consumables under each proposal would be a class 2 misdemeanor, punishable by up to 30 days in jail and a $500 fine.

Tighter rules on hemp products

The first bill, Senate Bill 61, aims to act as an outright ban on the possession, sale or use of any intoxicating hemp products in the state outside of licensed medical marijuana dispensaries.

Such products are typically produced by altering or distilling cannabidiol, or CBD, found in the hemp plant to produce forms of tetrahydrocannabinol, or THC, which is the intoxicating compound found in greater abundance in the marijuana plant.

Many of the gummies, vape cartridges and other products made using hemp-derived THC variants like Delta-8, Delta-9 or Delta-10 are sold primarily in smoke shops, but THC seltzers are often available at bars, liquor stores or grocery stores.

The products essentially act as a workaround for the prohibition of marijuana in South Dakota by anyone who lacks a medical marijuana card, Carley said. The senator is also a member of the state’s Medical Marijuana Oversight Committee, which has taken testimony from medical cannabis providers about the impact the unregulated market has on their operations.

“This actually is harming the licensed marijuana businesses,” Carley said.

Carley had the support of the South Dakota Police Chiefs’ Association, South Dakota Sheriff’s Association and a group called Protecting South Dakota Kids.

Opponents included representatives for hemp retailers and hemp growers and a handful of business owners, who said the bill’s ban on any products with more than 0.4 percent THC by weight would remove many non-intoxicating products from store shelves, including topical creams.

“All this is a hemp and CBD ban,” said Matt Yde, who sells CBD in Sioux Falls but does not offer intoxicating products. “I would have to close my store, because I would have to remove 90 percent of my products.”

Steve Siegel of the South Dakota Trial Lawyers Association said he’s had many friends who’ve switched to THC seltzers from alcohol or pain killers. He said their popularity shows consumer demand, and getting a medical marijuana card can be expensive and onerous.

“These drinks should be regulated. But they’re selling like wildfire,” Siegel said. “They’re a phenomenal alternative to alcohol.”

Carley responded by saying the state shouldn’t be encouraging people to switch from one mind-altering drug to another.

He was “sorry to hear” about people who’d been addicted to painkillers and alcohol, but said instead of switching to a THC alternative, “They need some friends there. They need some church. They need some God in their life, or even ice cream or tea.”

Keep reading

Ancient Cannabis Enzymes Reveal How THC and CBD First Evolved

Scientists are taking a deeper look at the origins of cannabis chemistry by reconstructing enzymes from ancient plants, offering new insight into how cannabis first developed the ability to produce compounds like THC and CBD.

In a recent study published in Plant Biotechnology Journal, researchers at Wageningen University & Research rebuilt molecular structures that existed millions of years ago, revealing that ancient forms of cannabis enzymes were more flexible and robust than those found in modern plants.

The team behind the research says they have successfully traced the evolution of cannabinoid chemistry and identified molecular tools that could improve the biotechnological production of modern medicinal cannabinoids.

The Origin of Cannabinoids

In modern cannabis plants, specialized enzymes are responsible for making individual cannabinoids like THC or CBD. Each enzyme is highly efficient at producing one specific compound. The new study shows that this precision is a recent development in cannabis evolution, rather than something that existed from the start.

Early ancestors of cannabis used versatile enzymes that could create several cannabinoids at once. These enzymes became more specialized over time as gene duplication occurred. This led to the distinct chemical profiles seen in cannabis plants today.

The research team provided direct evidence for this evolutionary process by reconstructing ancient cannabis enzymes in the lab. Their results show that the pathways for creating specific cannabinoids like THC appeared relatively recently and became more specialized over time through natural selection.

Rebuilding Lost Enzymes

The team relied on ancestral sequence reconstruction to study this evolutionary history. They compared DNA from modern cannabis and related species to determine what cannabinoid-producing enzymes looked like millions of years ago.

The researchers synthesized the predicted enzymes and tested their functions in the lab. Many of the reconstructed enzymes converted precursor molecules into several different cannabinoids, unlike the more specialized modern enzymes.

These experiments enabled the team to directly test evolutionary hypotheses that had previously relied solely on genetic comparisons.

Ancient Enzymes as Biotech Tools

The most immediate implications of the study are for biotechnology rather than evolutionary biology. When the researchers expressed ancient enzymes in microbial systems, they found that the reconstructed enzymes were often easier to use than those found in modern cannabis plants.

“What once seemed evolutionarily ‘unfinished’ turns out to be highly useful,” said Robin van Velzen, who led the study with colleague Cloé Villard. “These ancestral enzymes are more robust and flexible than their descendants, which makes them very attractive starting points for new applications in biotechnology and pharmaceutical research.”

Keep reading

‘Dark Money’ Anti-Marijuana Group Is Bankrolling Ballot Measures To Roll Back Legalization In Multiple States, Records Show

When it comes to putting a proposed new law before voters, it helps to have lots of money ready to burn.

More than $11 million has already changed hands to advance or oppose a potentially record-breaking field of ballot questions that Massachusetts voters could decide in November, according to newly filed campaign finance reports, including a significant injection by a national dark-money group that opposes legal drug use.

All $1.55 million raised so far in support of a proposal to recriminalize recreational marijuana in Massachusetts came from SAM Action Inc., an organization that is not required to disclose the source of its own funding.

It’s the same organization that bankrolled opposition to a 2024 Massachusetts ballot question that sought to open up access to some psychedelic substances, which voters rejected.

Massachusetts is not alone as a battleground, either. SAM Action is also the only donor behind a ballot question in Maine this cycle that would similarly prohibit recreational pot use there, as the Portland Press Herald reported.

Both campaigns have generated scrutiny over their efforts to gather signatures from voters.

In Massachusetts, opponents filed an objection alleging the campaign “obtained signatures fraudulently” by telling voters the measure would provide affordable housing or fund public parks, not that it would ban recreational marijuana.

The State Ballot Law Commission heard arguments last week and is expected to rule by Friday. State law empowers the panel to determine whether signatures were placed on a ballot question petition “by fraud,” and its interpretation could set off a lengthier court battle over whether the question can go before voters.

Similarly, Mainers have been alleging in recent weeks that they were misled about what the anti-marijuana petition would do when they signed it. Maine’s secretary of state, Shenna Bellows, said she’s received complaints about the topic, adding that she has no enforcement power because, as she put it to lawmakers, “You have a right to lie under the First Amendment.”

Wendy Wakeman, a veteran Republican operative who is working as spokesperson for the repeal campaign, said the Massachusetts and Maine questions are “not a coordinated effort” despite funding coming from the same national group.

SAM Action is a 501(c)(4) organization, so it’s not required to disclose its donors, leaving unclear exactly who is putting major dollars toward shutting down an industry both Massachusetts and Maine voted nearly a decade ago to legalize.

On its website, SAM Action claims affiliation with the nonprofit Smart Approaches to Marijuana group co-founded by former US Rep. Patrick Kennedy—a Democrat who represented Rhode Island, and the son of longtime US Sen. Ted Kennedy—along with former White House Office of National Drug Control Policy advisor Kevin Sabet and David Frum, a former speechwriter for President George W. Bush who is now a senior editor at The Atlantic.

Wakeman declined to comment on SAM Action’s primary donors.

Keep reading